Piramal Pharma Limited annonce ses résultats pour le deuxième trimestre et le premier semestre de l'exercice 2027

Piramal Pharma reported Q2FY27 operating revenue of ₹2,617 crore, up 28% year over year, and EBITDA of ₹385 crore, up 72%, with EBITDA margin rising to 14.7% from 11.0%. Q2 net profit after tax was ₹5 crore versus a ₹99 crore loss a year earlier; H1 revenue increased 23% to ₹4,887 crore, while H1 net loss after exceptional items narrowed to ₹64 crore from ₹181 crore. The company raised its FY27 revenue-growth forecast to 19%–20%, citing first-half performance and continued business momentum.

Analysis

The key question is whether operating leverage is becoming durable cash generation or is being amplified by utilization and project timing. CDMO growth can support further margin gains if new work converts into repeat production, but customer additions and audits are leading indicators—not proof of backlog conversion. CHG’s growth also includes Kenalog integration, so reported momentum may overstate the underlying run rate. A deceleration in either could expose the cost base before capacity is fully absorbed.

The balance sheet is the counterweight: net debt increased while the company added fixed and intangible assets. EBITDA improvement has not yet translated into meaningful after-tax earnings, with depreciation and interest absorbing much of the operating gain. Without cash-flow and capex detail, the quality of the upgrade remains unproven. The company’s second-half seasonality claim is not itself a catalyst unless order conversion and cash conversion confirm it.

Near term, the earnings upgrade may support sentiment, but chasing a sharp reaction risks paying for margin improvement before it is validated. Over 1–3 months, watch CDMO organic growth, segment margins, operating cash flow, and net debt. Over 6–18 months, successful utilization and debt reduction would support a more durable rerating; execution slippage, customer delays, or persistent investment needs would challenge it. The AbbVie joint-venture reference does not establish a material earnings read-through for AbbVie.

Key Decisions for Investors

• Do not chase the immediate post-results move without valuation and cash-flow context. Keep Piramal Pharma on a conditional long watchlist; consider entry after price consolidation only if the next update confirms CDMO growth and margin retention.
• Treat order additions and audit activity as conversion indicators, not booked revenue. Reassess the thesis if CDMO growth materially slows or consolidated EBITDA margin gives back the recent expansion.
• Make debt and cash conversion gating checks: verify operating cash flow, capex, and the drivers of higher net debt. Rising net debt alongside weaker cash generation would invalidate the quality-of-growth thesis, even if reported revenue remains strong.